Company profile
Aardvark Therapeutics, Inc. Common Stock
NASDAQ: AARD · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
40DFH 53DQ 20GM —SS 39
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$57.6M
Employees
40
as of 2026-08-14
Market cap
$140.3M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$57.6M-$57.6M2025
Operating income-$62.7M-$62.7M2025
Total assets$117.2M$117.2M2025
Liabilities$10.5M$10.5M2025
Equity$106.6M$106.6M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Aardvark Therapeutics, Inc. Common Stock’s revenue?
Aardvark Therapeutics, Inc. Common Stock booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
OnKure Therapeutics, Inc.46DTuHURA Biosciences, Inc.36DSpruce Biosciences, Inc.40DHelix BioPharma Corp.——Vivani Medical, Inc.33DFractyl Health, Inc.28DNeighbors
San Diego →Key facts
CEOTien-Li Lee
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: AARD
Employees40
IPO date2025-02-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.